- Home
- ESPR vs HLXB Comparison
ESPR vs HLXB Comparison
Compare ESPR & HLXB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- HLXB
- Stock Information
- Founded
- ESPR 2008
- HLXB 2021
- Country
- ESPR United States
- HLXB United States
- Employees
- ESPR N/A
- HLXB N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- HLXB
- Sector
- ESPR Health Care
- HLXB
- Exchange
- ESPR Nasdaq
- HLXB NYSE
- Market Cap
- ESPR 305.0M
- HLXB 253.2M
- IPO Year
- ESPR 2013
- HLXB 2024
- Fundamental
- Price
- ESPR $0.95
- HLXB $10.77
- Analyst Decision
- ESPR Buy
- HLXB
- Analyst Count
- ESPR 7
- HLXB 0
- Target Price
- ESPR $6.07
- HLXB N/A
- AVG Volume (30 Days)
- ESPR 5.5M
- HLXB 25.7K
- Earning Date
- ESPR 05-06-2025
- HLXB 01-01-0001
- Dividend Yield
- ESPR N/A
- HLXB N/A
- EPS Growth
- ESPR N/A
- HLXB N/A
- EPS
- ESPR N/A
- HLXB 0.36
- Revenue
- ESPR $332,314,000.00
- HLXB N/A
- Revenue This Year
- ESPR $5.17
- HLXB N/A
- Revenue Next Year
- ESPR N/A
- HLXB N/A
- P/E Ratio
- ESPR N/A
- HLXB $30.10
- Revenue Growth
- ESPR 185.66
- HLXB N/A
- 52 Week Low
- ESPR $0.93
- HLXB $10.14
- 52 Week High
- ESPR $3.94
- HLXB $11.59
- Technical
- Relative Strength Index (RSI)
- ESPR 22.73
- HLXB N/A
- Support Level
- ESPR $0.93
- HLXB N/A
- Resistance Level
- ESPR $1.06
- HLXB N/A
- Average True Range (ATR)
- ESPR 0.09
- HLXB 0.00
- MACD
- ESPR -0.02
- HLXB 0.00
- Stochastic Oscillator
- ESPR 3.57
- HLXB 0.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About HLXB HELIX ACQUISITION CORP. II
Helix Acquisition Corp II is a Blank check company.